The STEP 8 trial compared the weight loss efficacy of high-dose semaglutide against liraglutide at its approved dose for obesity (3 mg) in patients with T2D. Patients had a body weight reduction of 15.8% with semaglutide vs 6.4% with liraglutide.
In STEP 2, the higher dose of semaglutide (2.4 mg) achieved slightly better glycemic control, reductions in cardiometabolic risk, and improved physical function relative to the standard dose.
The STEP 1 trial involved patients who were obese or overweight without diabetes. More than 86% in the semaglutide group lost at least 5% of their body weight. In STEP 2, the average body weight reduction with 2.4 mg of semaglutide in patients with diabetes was 9.64%.
The STEP 4 trial found that participants who continued to take semaglutide lost an additional 7.9% of their body weight from weeks 20 to 48. This resulted in a total 17.4% weight loss over the whole trial. Those who switched to placebo after 20 weeks regained an average 6.9%, giving a total weight loss of 5%.
Take a clinical quiz on weight loss.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Semaglutide - Medscape - Jan 20, 2022.
Comments